An observational study in Myopia, Progressive, sponsored by Scripps Health. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2023-04-25.
Sponsored by Scripps Health · Observational
Progressive myopia can lead to severe vision loss and is associated with retinal detachment, glaucoma, and other comorbidities. Several studies have shown that off-label, low-dose atropine eye drops slow the progression of myopia. Many eye care providers are now prescribing off-label atropine eye drops for their myopic patients, with the prescribed concentrations varying amongst providers.
The purpose of this study is to determine if low-dose atropine eyedrops used daily, cause adverse effects to the eyes. Patients currently using 0.01%, 0.03%, or 0.05% atropine eye drops obtained from compounding pharmacies will be assessed for associated adverse effects.
Eligibility: Myopic patients currently using 0.01%, 0.03%, or 0.05% atropine eye drops, prescribed by the investigator(s).
Patients that meet the eligibility criteria will be given the parental consent form and child assent form (if applicable) during their regularly scheduled office visit. After consent forms are signed and at each follow-up visit, the investigator or study coordinator will begin by querying for adverse events by asking each patient general, non-directed questions, such as "How have you been feeling since the last visit?" Directed questioning and examination will then be done as appropriate. All reported adverse events will be documented on the appropriate CRF. The patients will then continue with their regular eye exam.
Patients enrolled in the study will be assessed for adverse events at each regularly scheduled office visit for the duration of the study (up to 5 years), unless they choose to withdraw from the study.
The study will assess 148 patients using either 0.01%, 0.03%, or 0.05% atropine eye drops (prescribed by the investigator), over a five-year period.
70 studies on the registry are indexed under Myopia, Degenerative; 19 are open to participants now.
This study's enrollment of 148 is close to the median of 148 across 11 observational studies indexed under Myopia, Degenerative.
Browse Myopia, Degenerative studies →Scripps Health is the lead sponsor of 45 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Pediatric patients diagnosed with myopia and using either 0.01%, 0.03%, or 0.05% atropine eye drops daily, prescribed by the principal investigator.
Exclusion Criteria:
0.01%, 0.03%, or 0.05% atropine eye drops made from compounding pharmacies.
Summary of adverse events by dose level at the time of the adverse event
Summary of total adverse events and severity of adverse events, by dose level at time of the adverse event
Time frame: up to 5 years
Summary of Source of Atropine
Summary of name of compounding pharmacy, cost of eye drops, size of the bottle of eye drops, and if there was a delay in obtaining eye drops from the compounding pharmacy.
Time frame: up to 5 years
Summary of adverse events by starting dose
Summary of adverse events by dose of atropine prescribed at start of study
Time frame: up to 5 years
Summary of demographics and medical history by atropine starting dose
Summary of demographics and medical history by atropine starting dose
Time frame: up to 5 years
Plan to share: No
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Scripps Health